|
業務類別
|
-- |
|
業務概覽
|
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its globalfootprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer. |
| 公司地址
| 3-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8426 |
| 電話號碼
| +81 362251111 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.daiichisankyo.co.jp |
| 員工數量
| 19765 |
| Mr. Takashi Matsumoto |
Director and Senior Executive Officer |
-- |
20/06/2025 |
| Mr. Hiroyuki Okuzawa |
Director, President and Chief Executive Officer |
-- |
20/06/2025 |
|
|
| Ms. Shizuko Ueno |
Director |
20/06/2025 |
| Mr. Joseph Kenneth Keller |
Director |
20/06/2025 |
| Ms. Reiko Kinoshita |
Independent Director |
20/06/2025 |
| Mr. Sunao Manabe |
Executive Chairman of the Board |
20/06/2025 |
| Mr. Akihiro Watanabe |
Independent Director |
20/06/2025 |
| Mr. Takaaki Nishii |
Independent Director |
20/06/2025 |
| Mr. Takashi Matsumoto |
Director and Senior Executive Officer |
20/06/2025 |
| Mr. Hiroyuki Okuzawa |
Director, President and Chief Executive Officer |
20/06/2025 |
| Mr. Yo Honma |
Independent Director |
20/06/2025 |
| Mr. Yasuhiro Komatsu |
Independent Director |
20/06/2025 |
|
|
|
|
